| Literature DB >> 35975970 |
Yang Liu1, Zexi Li1, Anlei Liu1, Jun Xu1, Yi Li1, Jihai Liu1, Yecheng Liu1, Huadong Zhu1.
Abstract
BACKGROUND: Percutaneous catheter drainage (PCD) has been viewed as first-line treatment for pyogenic liver abscess (PLA), yet detailed guidance is lacking for best practice of PCD. This study investigated characteristics of patients with PLA who had received PCD, identified factors associated with prolonged fever, and aimed to evaluate the relationship between timing of PCD and clinical improvement.Entities:
Keywords: Percutaneous catheter drainage; early; loculation; prolonged fever; pyogenic liver abscess
Mesh:
Year: 2022 PMID: 35975970 PMCID: PMC9387318 DOI: 10.1080/07853890.2022.2110612
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 5.348
Figure 1.Contrast-enhanced CT images of pyogenic liver abscesses (asterisks): (a) liquified liver abscess; (b) liver abscess with non-liquified content.
Characteristics of patients with pyogenic liver abscesses.
| Variables | |
|---|---|
| Age (years) | 56.9 ± 13.9 |
| Sex (male) | 56 (69.1%) |
| Diabetes mellitus | 39 (48.1%) |
| History of benign hepatobiliary disease | 25 (30.9%) |
| Previous history of PLA | 2 (2.5%) |
| Hepatic cyst | 3 (3.7%) |
| Fatty liver | 6 (7.4%) |
| Cholelithiasis | 12 (14.8%) |
| Cholecystitis | 2 (2.5%) |
| Hepatopancreatobiliary malignancy | 11 (13.6%) |
| Hepatocellular carcinoma | 2 (2.5%) |
| Metastatic hepatic cancer | 1 (1.2%) |
| Gallbladder cancer or cholangiocarcinoma | 3 (3.7%) |
| Pancreatic or ampullary malignancy | 5 (6.2%) |
| Abdominal surgery/intervention history | 26 (32.1%) |
| Liver abscess drainage | 1 (1.2%) |
| Liver cancer radiofrequency ablation | 1 (1.2%) |
| Liver cancer interventional therapy | 2 (2.5%) |
| Liver resection | 3 (3.7%) |
| Pancreatobiliary surgery | 7 (8.6%) |
| Other abdominal surgery | 12 (14.8%) |
| Prodrome | |
| Enteric infection | 10 (12.3%) |
| Respiratory tract infection | 15 (18.5%) |
| Symptom | |
| Abdominal pain | 39 (48.1%) |
| Jaundice | 9 (11.1%) |
| Diameter of abscess (cm) | 7.6 (6.1–9.3) |
| Site of abscess | |
| Right lobe | 59 (72.8%) |
| Left lobe | 16 (19.8%) |
| Bilobar | 5 (6.2%) |
| Caudate lobe | 1 (1.2%) |
| Number of abscesses | |
| Single | 54 (66.7%) |
| Multiple | 27 (33.3%) |
| Multiloculated abscesses | 67 (82.7%) |
| Positive blood culturea | 20/73 (27.4%) |
| Positive pus cultureb | |
|
| 49 (60.5%) |
|
| 2 (2.5%) |
|
| 7 (8.6%) |
| 6 (7.4%) | |
|
| 5 (6.2%) |
|
| 2 (2.5%) |
|
| 1 (1.2%) |
|
| 1 (1.2%) |
| Period before PCD insertion after admission (days) | 4 (2–7) |
| Period before PCD insertion after fever onset (days) | 17 (11–26) |
| Complications with PCD treatment | |
| Pleural effusion | 14 (17.3%) |
| Pneumonia | 8 (9.9%) |
| Acute renal failure | 2 (2.5%) |
| Pneumothorax | 1 (1.2%) |
| Intraperitoneal bleeding | 1 (1.2%) |
| Length of hospital stay (days) | 25 (19–33) |
Data were presented as number (percentage), mean ± standard deviation or median (IQR), as appropriate.
PCD: percutaneous catheter drainage.
aBlood cultures of eight cases were not performed.
bFour patients had mixed infections with two or more microbes.
Blood and pus culture positivity in patients with pyogenic liver abscesses.
| Blood culture | |||||
|---|---|---|---|---|---|
| Positive | Negative | N/A | Total | ||
| Pus culture | Positive | 18 (22.2%) | 43 (53.1%) | 7 (8.7%) | 68 (84.0%) |
| Negative | 2 (2.5%) | 10 (12.3%) | 1 (1.2%) | 13 (16.0%) | |
| Total | 20 (24.7%) | 53 (65.4%) | 8 (9.9%) | 81 (100%) | |
Data were presented as number (percentage).
N/A: not available.
Figure 2.Time to defervescence was associated with timing of PCD treatment. (a) Days to defervescence were compared between early PCD and delayed PCD groups. Error bars, mean ± SEM. (b) Time for temperature normalization was significantly shortened with early PCD intervention. p Value, log-rank test. (c) Time to defervescence differed among groups stratified by timing of PCD treatment. Error bars, mean ± SEM.
Comparison of patients with early and delayed PCD treatment.
| Variables | Early PCD ( | Delayed PCD ( | |
|---|---|---|---|
| Age (years) | 57.5 ± 12.8 | 56.7 ± 14.4 | .768 |
| Sex (male) | 14 (58.3%) | 42 (73.7%) | .172 |
| Diabetes mellitus | 10 (41.7%) | 29 (50.9%) | .449 |
| Abdominal pain | 18 (75%) | 21 (36.8%) | .002 |
| Jaundice | 2 (8.3%) | 7 (12.3%) | .718 |
| Maximum body temperature (°C) | 39.4 ± 1.2 | 39.6 ± 0.8 | .490 |
| 13 (54.2%) | 23 (40.4%) | .253 | |
| MAP at admission (mmHg) | 90.1 ± 14.9 | 91.1 ± 12.2 | .721 |
| WBC (109/L) | 14.25 (9.15–18.05) | 11.83 (8.62–15.98) | .280 |
| Neutrophil (109/L) | 11.91 (7.27–15.81) | 9.59 (7.08–13.70) | .170 |
| Lymphocyte (109/L) | 0.89 (0.41–1.36) | 1.06 (0.74–1.52) | .303 |
| Hemoglobin (g/L) | 112.6 ± 19.9 | 109.5 ± 17.1 | .901 |
| Platelet (109/L) | 252.6 ± 172.8 | 259.4 ± 139.1 | .779 |
| Lactate dehydrogenase (U/L) | 263.5 (222.5–388) | 236 (202–269) | .293 |
| PCT (ng/mL) | ( | ( | .837 |
| <0.5 | 5 (27.8%) | 14 (32.6%) | |
| 0.5–2 | 3 (16.7%) | 10 (23.3%) | |
| 2–10 | 4 (22.2%) | 9 (20.9%) | |
| ≥10 | 6 (33.3%) | 10 (23.3%) | |
| Alanine aminotransferase (U/L) | 42 (20.5–90.5) | 54 (32–85) | .444 |
| Albumin (g/L) | 32 (29–35) | 30 (27–33) | .129 |
| Total bilirubin (μmol/L) | 13.25 (9.75–30.4) | 13 (9.7–22) | .873 |
| Direct bilirubin (μmol/L) | 5.1 (3.6–19.05) | 5.4 (4.3–12.7) | .664 |
| Creatinine (μmol/L) | 70 (56–89) | 67 (59–83) | .873 |
| Urea (mmol/L) | 5.45 (4.03–8.87) | 4.5 (3.63–5.82) | .094 |
| PT (s) | 14.05 (13.15–14.95) | 14.2 (13.5–15.3) | .820 |
| APTT (s) | 31.75 (29.55–37.5) | 32.8 (30–38) | .721 |
| Diameter of abscess (cm) | 7.3 (5.95–8.95) | 7.84 (6.47–9.6) | .374 |
| Catheter adjustment | 3 (12.5%) | 4 (7.0%) | .417 |
| Secondary PCD required | 5 (20.8%) | 8 (14.0%) | .513 |
| Bacteraemia | 8/24 (33.3%) | 12/49 (24.5%) | .577 |
| Septic shock | 7 (29.2%) | 10 (17.5%) | .241 |
| ICU admission | 6 (25.0%) | 8 (14.0%) | .334 |
| Time to defervescence (days) | 17 (8.5–29.5) | 22 (17–36) | .042 |
Data were presented as number (percentage), mean ± standard deviation or median (IQR), as appropriate.
MAP: mean arterial pressure; WBC: white blood cell; PCT: procalcitonin; PT: prothrombin time; APTT: activated partial thromboplastin time; PCD: percutaneous catheter drainage; ICU: intensive care unit.
Comparisons of clinical features, laboratory parameters and managements in patients grouped by duration of fever.
| Variables | Febrile period | Febrile period | |
|---|---|---|---|
| ≤ 15 days ( | > 15 days ( | ||
| Age (years) | 56.7 ± 15.1 | 57.0 ± 13.5 | .963 |
| Sex (male) | 19 (79.2%) | 37 (64.9%) | .205 |
| Diabetes mellitus | 8 (33.3%) | 31 (54.4%) | .083 |
| Hepatopancreatobiliary malignancy | 6 (25.0%) | 5 (8.77%) | .075 |
| Abdominal surgery history | 9 (37.5%) | 17 (29.8%) | .499 |
| Maximum body temperature (°C) | 39.2 ± 1.0 | 39.7 ± 0.8 | .050 |
| 11 (45.8%) | 25 (43.9%) | .870 | |
| MAP at admission (mmHg) | 93.0 ± 16.0 | 89.9 ± 11.5 | .189 |
| WBC (109/L) | 16.61 (9.15–18.48) | 11.83 (8.60–15.22) | .106 |
| Neutrophil (109/L) | 14.11 (7.41–16.91) | 9.82 (6.70–12.56) | .076 |
| Lymphocyte (109/L) | 0.98 (0.41–1.36) | 1.04 (0.72–1.52) | .816 |
| Hemoglobin (g/L) | 116.4 ± 20.5 | 107.9 ± 16.3 | .089 |
| Platelet (109/L) | 281.1 ± 171.8 | 247.8 ± 138.5 | .437 |
| Lactate dehydrogenase (U/L) | 230.5 (214–291) | 243 (201–293) | .953 |
| PC | 9/18 (50.0%) | 20/43 (46.5%) | .804 |
| Alanine aminotransferase (U/L) | 45 (20.5–81) | 48 (31–85) | .344 |
| Albumin (g/L) | 31 (29–33) | 31 (26–35) | .671 |
| Total bilirubin (μmol/L) | 18.2 (9.75–43.15) | 12.2 (9.7–18.9) | .126 |
| Direct bilirubin (μmol/L) | 10.7 (4.05–29.45) | 5.1 (4–11.3) | .161 |
| Creatinine (μmol/L) | 72 (57–102) | 66 (57–81) | .187 |
| Urea (mmol/L) | 5.46 (3.95–8.38) | 4.67 (3.77–5.82) | .192 |
| Blood glucose at admission (mmol/L) | 6.5 (5.7–8.6) | 8.3 (6.0–10.6) | .069 |
| PT (s) | 14.2 (13.65–15.3) | 14.1 (13.2–14.7) | .382 |
| APTT (s) | 32.45 (29.1–39.35) | 32.1 (30–37.8) | .812 |
| Positive blood culture | 4/21 (19.0%) | 16/52 (30.8%) | .309 |
| 13 (54.2%) | 36 (63.2%) | .450 | |
| Multiple abscess cavities | 5 (20.8%) | 22 (38.6%) | .121 |
| Abscess location (right lobe only) | 16 (66.7%) | 43 (75.4%) | .418 |
| Multiloculated abscess | 18 (75.0%) | 49 (86.0%) | .334 |
| Diameter of abscess > 7.5 cm | 8 (33.3%) | 33 (57.9%) | .043 |
| Early PCD treatment | 12 (50.0%) | 12 (21.1%) | .009 |
| Catheter adjustment | 2 (8.3%) | 5 (8.8%) | 1.000 |
| Secondary procedure required | 1 (4.2%) | 12 (21.1%) | .095 |
| PCD complications | 7 (29.2%) | 19 (33.3%) | .714 |
| Outcomes | |||
| Septic shock | 6 (25.0%) | 11 (19.3%) | .565 |
| ICU admission | 6 (25.0%) | 8 (14.0%) | .334 |
| Time for WBC normalization (days) | 5.5 (2–10) | 8.5 (3.5–12.5) | .142 |
| Length of hospital stay (days) | 20.5 (16.5–27) | 28 (21–38) | .005 |
Data were presented as number (percentage), mean ± standard deviation or median (IQR), as appropriate.
MAP: mean arterial pressure; WBC: white blood cell; PCT: procalcitonin; PT: prothrombin time; APTT: activated partial thromboplastin time; KP: Klebsiella pneumoniae; PCD: percutaneous catheter drainage; ICU: intensive care unit.
Factors associated with prolonged fever (>15 days) in patients with pyogenic liver abscesses.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | Odds ratio | 95% CI | |||
| Maximum body temperature (°C) | 1.728 | 1.001–2.983 | .049 | 1.556 | 0.866–2.795 | .139 |
| Diameter of absces | 2.750 | 1.013–7.463 | .047 | 2.269 | 0.789–6.522 | .128 |
| Early PCD treatment | 0.267 | 0.096–0.741 | .011 | 0.305 | 0.105–0.890 | .030 |
PCD: percutaneous catheter drainage; CI: confidence interval.